
Chemed (CHE) Stock Forecast & Price Target
Chemed (CHE) Analyst Ratings
Bulls say
Chemed Corp's positive outlook is supported by strong demand growth in both its VITAS and Roto-Rooter segments. The VITAS segment, being the nation's leading hospice provider, has demonstrated significant long-term growth potential and profitability improvements, even amid competitive pressures and regulatory caps in specific markets like Florida. Additionally, projections indicate that VITAS is set to rebound in 2026, which, combined with an improving economic landscape, suggests favorable conditions for continued revenue acceleration.
Bears say
Chemed Corp faces several financial challenges projected to impact its future earnings and growth. The anticipated macroeconomic headwinds are expected to soften consumer demand for both the Roto-Rooter and VITAS segments, leading to a downward revision of FY2025 to FY2027 earnings per share estimates by 10% and lowering the price target significantly. Additionally, operational difficulties are exemplified by a 520 basis point decline in Roto-Rooter's adjusted EBITDA margin and a year-over-year decrease in lead generation, highlighting concerns over increased costs and reduced demand that could adversely affect overall profitability.
This aggregate rating is based on analysts' research of Chemed and is not a guaranteed prediction by Public.com or investment advice.
Chemed (CHE) Analyst Forecast & Price Prediction
Start investing in Chemed (CHE)
Order type
Buy in
Order amount
Est. shares
0 shares